Nuvation Bio (NYSE:NUVB) raced as much as 8% on Friday after SEC filings showed that insiders in the company bought shares ...

Despite a strong cash position and no debt, my NPV model shows NUVB is fairly valued or overvalued at $1.73. Click here to ...

Nuvation Bio Inc. ( NYSE:NUVB ) shareholders (or potential shareholders) will be happy to see that the Founder, ...

Read the latest analysis on Nuvation Bio stock. Solid financials, positive analyst sentiment, and insider buying support ...

The drug, Ibtrozi, will now vie for market share in an indication where multiple large pharmaceutical companies have already ...

Nuvation Bio is set to launch its first commercial product after the FDA approved its ROS1 inhibitor Ibtrozi as a treatment ...

He has a track record of turning drug approvals into billion-dollar deals. Patience pays off for this biotech deal © 2025 ...

FDA approves Ibtrozi for ROS1+ non-small cell lung cancer based on data from over 300 patients in two pivotal trials showing ...

This next-generation ROS1 tyrosine kinase inhibitor previously received breakthrough therapy and orphan drug designations for ...

The US Food and Drug Administration (FDA) has approved Nuvation Bio’s Ibtrozi (taletrectinib) to treat adults with a rare and ...